Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $29.02, for a total transaction of $435,300.00. Following the sale, the chief executive officer directly owned 686,907 shares of the company’s stock, valued at approximately $19,934,041.14. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Cameron Turtle also recently made the following trade(s):

• On Monday, November 3rd, Cameron Turtle sold 45,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $23.33, for a total transaction of $1,049,850.00.

Spyre Therapeutics Stock Up 13.4%

Shares of NASDAQ SYRE traded up $3.80 on Wednesday, hitting $32.20. The company had a trading volume of 1,313,359 shares, compared to its average volume of 681,008. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $32.26. The business has a 50 day moving average of $22.65 and a two-hundred day moving average of $18.42. The firm has a market capitalization of $2.50 billion, a P/E ratio of -14.70 and a beta of 3.14.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Tuesday, November 4th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.53. On average, sell-side analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Jones Trading upgraded shares of Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a research note on Monday. BTIG Research reissued a “buy” rating and set a $70.00 target price on shares of Spyre Therapeutics in a research note on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft began coverage on Spyre Therapeutics in a research note on Friday, September 26th. They issued a “buy” rating and a $43.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Spyre Therapeutics in a report on Tuesday, November 25th. Finally, Wedbush restated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Spyre Therapeutics has a consensus rating of “Buy” and an average target price of $52.33.

Institutional Trading of Spyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC lifted its position in shares of Spyre Therapeutics by 357.8% during the 2nd quarter. CWM LLC now owns 1,712 shares of the company’s stock worth $26,000 after purchasing an additional 1,338 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Spyre Therapeutics by 45.2% during the 1st quarter. AlphaQuest LLC now owns 3,191 shares of the company’s stock valued at $51,000 after acquiring an additional 993 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Spyre Therapeutics by 2,881.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock worth $71,000 after buying an additional 4,092 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Spyre Therapeutics by 25.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,091 shares of the company’s stock valued at $76,000 after purchasing an additional 1,045 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Spyre Therapeutics by 182.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock worth $86,000 after acquiring an additional 3,725 shares during the last quarter. 80.39% of the stock is currently owned by institutional investors and hedge funds.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).